Jeffrey Alliston, MD
Urology · Rogers, ARNPI 1811382906
Payments from drug & device makers
What this record shows
This record is dominated by education: $12,129 of the $16,705 with a category attached, or 72.6%. Intuitive Surgical accounts for 71.8% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2021 at $12,423 and has fallen 93.7% since, to $780 in 2025.
Across 146 payments — averaging $114.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$12K
- Axonics, Inc.$2K
- Boston Scientific$316
- Medtronic$283
- Coloplast$239
- Calyxo, Inc.$231
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$2582%
- Travel & lodging$1,1207%
- Food & beverage$3,19919%
- Education$12,12973%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 4 | $12,000 |
| Axonics, Inc. | 28 | $2,050 |
| Boston Scientific | 10 | $316 |
| Medtronic | 14 | $283 |
| Coloplast | 13 | $239 |
| Calyxo, Inc. | 1 | $231 |
| Agiliti Health, Inc. | 5 | $200 |
| Sumitomo Pharma America, Inc. | 8 | $168 |
| Astellas Pharma US Inc | 3 | $126 |
| AbbVie | 7 | $123 |
| Endo Pharmaceuticals Inc. | 7 | $108 |
| Urogen Pharma, Inc. | 5 | $97 |
| Cook Medical LLC | 1 | $81 |
| Merck | 4 | $75 |
| Myovant Sciences Inc. | 4 | $67 |
| Blue Earth Diagnostics | 3 | $59 |
| Bayer | 3 | $52 |
| Antares Pharma, Inc. | 3 | $45 |
| Clarus Therapeutics Inc. | 3 | $39 |
| Olympus America Inc. | 2 | $38 |
| Dexcom, Inc. | 3 | $36 |
| AstraZeneca | 1 | $35 |
| ABC Home Medical Supply, Inc. | 1 | $30 |
| Novartis | 1 | $26 |
| Teleflex LLC | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $17 |
| 180 Medical, Inc. | 1 | $17 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Ambu Inc. | 1 | $17 |
| Laborie Medical Technologies Corp. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$12,000
- Axonics$1,499
- CVAC Aspiration System$231
How this compares
$16,705 in reported general payments places this provider in the 70th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 105 | $86,158 |
| GemtesaVibegron | 94 | $85,524 |
| Tamsulosin Hcl | 676 | $9,792 |
| PremarinEstrogens, Conjugated | 14 | $6,313 |
| Finasteride | 246 | $3,241 |
| Oxybutynin Chloride ErOxybutynin Chloride | 164 | $2,800 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 60 | $1,825 |
| Testosterone Cypionate | 71 | $1,567 |
| Estradiol | 21 | $1,364 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 45 | $979 |
| Trospium Chloride ErTrospium Chloride | 15 | $943 |
| Terazosin Hcl | 45 | $593 |
| Solifenacin Succinate | 25 | $557 |
| Tadalafil | 25 | $469 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 50 | $293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $126 | $86,158105 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $168 | $85,52494 claims |
| PfizerPremarin | $18 | $6,31314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 88 urology providers in Arkansas.
Other urology in Rogers
- Robert ZimmermanRogers$15K
- Christopher CampbellRogers$13K
- Matthew KincadeRogers$9K
- William BrockwayRogers$3K
- Orlando Aguilar-GuzmanRogers$3K
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Ronald KuhnNorth Little Rock$138K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.